Literature DB >> 15257081

Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury.

Toshiaki Hayakata1, Tadahiko Shiozaki, Osamu Tasaki, Hitoshi Ikegawa, Yoshiaki Inoue, Fujinaka Toshiyuki, Hideo Hosotubo, Fuijita Kieko, Testuji Yamashita, Hiroshi Tanaka, Takeshi Shimazu, Hisashi Sugimoto.   

Abstract

S100B protein (S100B) has been described as a marker of brain injury. Various cytokines also increase in the cerebrospinal fluid (CSF) of patients with severe traumatic brain injury (TBI). Thus, we investigated early changes in the concentrations of CSF S100B and various cytokines after TBI and evaluated the relations of both S100B and cytokines to intracranial pressure (ICP) and prognosis. Twenty-three patients with severe TBI and a Glasgow Coma Scale score of 8 or less on admission were included in this study. CSF and serum samples were obtained on admission and at 6, 12, 24, 48, 72, and 96 h after injury. CSF concentrations of S100B and CSF and serum concentrations of five cytokines (IL-1beta, TNF-alpha, IL-6, IL-8, and IL-10) were measured and compared. The CSF S100B concentration was increased for 6 h after injury and decreased thereafter. The CSF concentrations of IL-6 and IL-8 peaked within 6 h after injury; other cytokines (IL-1beta, TNF-alpha, and IL-10) were elevated for 24 h after injury and gradually decreased thereafter. Peak CSF S100B concentrations correlated significantly with ICP determined at the time CSF samples were taken (r = 0.729, P < 0.0001). For the cytokines investigated, only the peak CSF IL-1beta concentration correlated significantly and positively with the peak CSF S100B concentration (r = 0.397, P < 0.005). Peak CSF concentrations of S100B (1649 +/- 415 microg/L, mean +/- SEM) and IL-1beta (16.5 +/- 3.3 pg/mL) in the 6 patients with high ICP were significantly higher than those (233 +/- 67 microg/L, 7.6 +/- 1.7 pg/mL, respectively) in the 17 patients with low ICP (P < 0.05). The CSF S100B concentration (1231 +/- 378 microg/L) in eight patients with an unfavorable outcome was significantly higher than that (267 +/- 108 microg/L) in 15 patients with a favorable outcome (P < 0.05). The CSF IL-1beta concentration (14.8 +/- 3.4 pg/mL) in eight patients with an unfavorable outcome tended to be higher than that (7.3 +/- 1.5 pg/mL) in 15 patients with a favorable outcome (P = 0.057). CSF concentrations of S100B and cytokines peak within 24 h after severe TBI and decrease gradually thereafter. CSF S100B and IL-1beta may be useful as predictors of outcome in cases of severe TBI.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257081     DOI: 10.1097/01.shk.0000131193.80038.f1

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  66 in total

Review 1.  How to Translate Time: The Temporal Aspects of Rodent and Human Pathobiological Processes in Traumatic Brain Injury.

Authors:  Denes V Agoston; Robert Vink; Adel Helmy; Mårten Risling; David Nelson; Mayumi Prins
Journal:  J Neurotrauma       Date:  2019-03-07       Impact factor: 5.269

2.  Homogeneous immunosubtraction integrated with sample preparation enabled by a microfluidic format.

Authors:  Akwasi A Apori; Amy E Herr
Journal:  Anal Chem       Date:  2011-03-04       Impact factor: 6.986

Review 3.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

Review 4.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

5.  YKL-40 expression in traumatic brain injury: an initial analysis.

Authors:  Dafna Bonneh-Barkay; Pavel Zagadailov; Huichao Zou; Christian Niyonkuru; Matthew Figley; Adam Starkey; Guoji Wang; Stephanie J Bissel; Clayton A Wiley; Amy K Wagner
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

Review 6.  Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift.

Authors:  Yasir N Jassam; Saef Izzy; Michael Whalen; Dorian B McGavern; Joseph El Khoury
Journal:  Neuron       Date:  2017-09-13       Impact factor: 17.173

7.  Therapeutic targeting of astrocytes after traumatic brain injury.

Authors:  Jessica Shields; Donald E Kimbler; Walid Radwan; Nathan Yanasak; Sangeetha Sukumari-Ramesh; Krishnan M Dhandapani
Journal:  Transl Stroke Res       Date:  2011-11-09       Impact factor: 6.829

8.  Hemorrhagic shock shifts the serum cytokine profile from pro- to anti-inflammatory after experimental traumatic brain injury in mice.

Authors:  Steven L Shein; David K Shellington; Jennifer L Exo; Travis C Jackson; Stephen R Wisniewski; Edwin K Jackson; Vincent A Vagni; Hülya Bayır; Robert S B Clark; C Edward Dixon; Keri L Janesko-Feldman; Patrick M Kochanek
Journal:  J Neurotrauma       Date:  2014-08-15       Impact factor: 5.269

9.  Telmisartan reduced cerebral edema by inhibiting NLRP3 inflammasome in mice with cold brain injury.

Authors:  Xin Wei; Chen-Chen Hu; Ya-Li Zhang; Shang-Long Yao; Wei-Ke Mao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

10.  Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis.

Authors:  A Calcagno; A Romito; C Atzori; V Ghisetti; C Cardellino; S Audagnotto; E Scarvaglieri; F Lipani; D Imperiale; G Di Perri; S Bonora
Journal:  J Neuroimmune Pharmacol       Date:  2016-11-08       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.